Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25653647 | 0.90 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL24336460 | 0.85 | SMYD2 (0.31) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL28573427 | 0.76 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22845189 | 0.76 | NT5E (0.37) | — | |
| SCHEMBL21777024 | 0.76 | NT5E (0.37) | — | |
| SCHEMBL29654867 | 0.76 | NT5E (0.37) | — | |
| SCHEMBL28563371 | 0.74 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL26122179 | 0.73 | MAPT (0.32) | — | |
| SCHEMBL8175539 | 0.72 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL29846198 | 0.72 | ACACB (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035371-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12240853-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20240182473-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20220411425-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220117993-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174534-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, LSS | SMYD2 3024/4885CYP3A4 134/4885HTT 2455/4885 |
| US-20260035371-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CCR1, CYC1 | SMYD2 3356/4885CYP3A4 151/4885HTT 3594/4885 |
| US-20220117993-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, ABCB1 | SMYD2 3472/4885CYP3A4 104/4885HTT 2347/4885 |
| US-20240182473-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CD4, CCR5, G6PD | SMYD2 3529/4885CYP3A4 261/4885HTT 2919/4885 |
| US-12240853-B2 | Compounds useful in HIV therapy | CCR5, CD4, LSS | SMYD2 3024/4885CYP3A4 134/4885HTT 2455/4885 |
| US-20220411425-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, NFATC1 | SMYD2 2461/4885CYP3A4 575/4885HTT 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.